HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consumer protection bill

This article was originally published in The Rose Sheet

Executive Summary

HR 2621 moves to the Senate after passing lower chamber June 11 by voice vote. Measure would amend the Federal Anti-Tampering Act by making it a crime to "knowingly stamp, print, place or insert any writing in or on any consumer product...prior to its sale" without the consent of the product's manufacturer, distributor or retailer. Consumer Product Protection Act of 2002, introduced last July by Rep. Melissa Hart (D-Penn.) and amended May 8, was spurred by recent product tampering cases primarily in the food industry. Speaking about the bill, Rep. Tammy Baldwin (D-Wisc.) notes "it has become clear that law enforcement officials lack the authority to prosecute these crimes under state or federal law." The Cosmetic, Toiletry & Fragrance Association supports the bill...

You may also be interested in...

Industry Delighted By ‘Fixed’ USMCA

Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts